Most Read Articles
Roshini Claire Anthony, 09 Jul 2020

Children who are fully vaccinated against the flu, ie, receive the recommended number of influenza vaccine doses, have a lower risk of acquiring influenza compared with those who are partially vaccinated, a US study found.

06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
2 days ago
Treatment with levothyroxine appears to have no significant impact on systolic and diastolic heart function in older adults with mild subclinical hypothyroidism as compared with placebo, results of a study have shown.
Roshini Claire Anthony, 08 Jul 2020

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Dulaglutide shows consistent efficacy in reducing HbA1c, body weight in T2D patients

03 Jun 2020

The glucagon-like peptide-1 (GLP-1) receptor agonist (RA) dulaglutide shows highly consistent effectiveness on glycated haemoglobin (HbA1c) and body weight reduction in patients with type 2 diabetes (T2D), reveals a study. Its effectiveness remains significant even in subgroups of patients poorly represented in randomized controlled trials (RCTs).

In this retrospective multicentre study, the investigators assessed the effectiveness of dulaglutide in routine clinical practice, particularly in subgroups of patients who are underrepresented in RCTs. Participants included all consecutive patients who initiated dulaglutide between 2015 and 2018.

The investigators evaluated changes in HbA1c and body weight up to 30 months after baseline. They also analysed effectiveness in patient subgroups based on the following: prior use of GLP-1RA, persistence on treatment and dose, age, sex, disease duration, renal function, obesity, cardiovascular disease, or concomitant use of insulin or sulphonylurea.

A total of 83,116 patients were included, of which 2,084 initiated dulaglutide (15.3 percent switching from another GLP-1RA) and 1,307 had at least one follow-up visit. At the end of observation, dulaglutide effectively reduced HbA1c by 1.0 percent and body weight by 2.9 kg, with the effects being more evident in GLP-1RA–naïve patients and in those with shorter disease duration.

Highly significant and consistent improvements were observed across all subgroups, including those aged ≥75 years, nonobese, or with chronic kidney disease. In addition, body weight decreased in all subgroups and significantly more with the 1.5- vs 0.75-mg dose.

RCTs on T2D patients showed that dulaglutide reduced HbA1c and body weight, but generalizability of these findings to real-world T2D patients remains a challenge, according to the investigators.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 09 Jul 2020

Children who are fully vaccinated against the flu, ie, receive the recommended number of influenza vaccine doses, have a lower risk of acquiring influenza compared with those who are partially vaccinated, a US study found.

06 Jul 2020
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
2 days ago
Treatment with levothyroxine appears to have no significant impact on systolic and diastolic heart function in older adults with mild subclinical hypothyroidism as compared with placebo, results of a study have shown.
Roshini Claire Anthony, 08 Jul 2020

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.